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Objectives: The p38 mitogen-activated protein kinase (MAPK) signal transduction pathway is 
involved in a variety of inflammatory responses, including cytokine generation, cell differentiation 
proliferation and apoptosis. Here, we examined the effects of systemic p38 MAPK inhibition on 
cartilage cells and osteoarthritis (OA) disease progression by both in vitro and in vivo approaches.  
Methods: p38 kinase activity was evaluated in normal and OA cartilage cells by measuring the 
amount of phosphorylated protein. To examine the function of p38 signaling pathway in vitro, 
normal chondrocytes were isolated and differentiated in the presence or absence of p38 inhibitor; 
SB203580 and analysed for chondrogenic phenotype. Effect of systemic p38 MAPK inhibition in 
normal and OA (induced by menisectomy) rats were analysed by treating animals with vehicle alone 
(DMS0) or p38 inhibitor (SB203580). Damage to the femur and tibial plateau was evaluated by 
modified Mankin score, histology and immunohistochemistry.  
Results: Our in vitro studies have revealed that a down-regulation of chondrogenic and increase of 
hypertrophic gene expression occurs in the normal chondrocytes, when p38 is neutralized by a 
pharmacological inhibitor.  We further observed that the basal levels of p38 phosphorylation were 
decreased in OA chondrocytes compared with normal chondrocytes. These findings together 
indicate the importance of this pathway in the regulation of cartilage physiology and its relevance to 
OA pathogenesis. At in vivo level, systematic administration of a specific p38 MAPK inhibitor, 
SB203580, continuously for over a month led to a significant loss of proteoglycan; aggrecan and 
cartilage thickness. On the other hand, SB203580 treated normal rats showed a significant increase 
in TUNEL positive cells, cartilage hypertrophy markers such as Type 10 collagen, Runt-related 
transcription factor and Matrix metalloproteinase-13 and substantially induced OA like phenotypic 
changes in the normal rats. In addition, menisectomy induced OA rat models that were treated with 
p38 inhibitor showed aggravation of cartilage damage.  
Conclusions: In summary, this study has provided evidence that the component of the p38 MAPK 
pathway is important to maintain the cartilage health and its inhibition can lead to severe cartilage 
degenerative changes. The observations in this study highlight the possibility of using activators of 
the p38 pathway as an alternative approach in the treatment of OA. 
 
 
INTRODUCTION 
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Osteoarthritis (OA), the most common multifactorial degenerative joint disease in the elderly, is 
characterized by the degeneration of articular cartilage, changes in subchondral bone, osteophyte 
formation and synovial inflammation. The cause of OA is still unknown and many mechanical, 
biochemical and molecular factors are known to be involved. In the progression of OA, the balance 
of synthesis and degradation of articular cartilage shifts towards catabolism [1]. These synthetic 
changes involve alterations in specific signaling molecules and their respective downstream 
pathways [2]. Among the most conserved signal transduction systems in the cartilage is the mitogen-
activated protein kinase (MAPK) cascade, which consists of sequentially acting protein kinases 
resulting in the activation of three terminal MAP kinases: p38 kinase, extracellular signal-regulated 
protein kinase (ERK), and c-jun N-terminal protein kinase (JNK)[3]. 
It has been reported that p38 signaling controls terminal differentiation [4], proliferation and 
differentiation of chondrocytes with a delicate balance, interacting with the TGF-β1/Smads signalling 
pathway [5, 6]. Our observations indicate that the p38 pathway plays a major positive role in 
regulating the articular chondrogenic phenotype and its expression negatively regulates cartilage 
hypertrophic phenotype [7]. Although p38 kinases were originally cloned as mediators of growth and 
development, recent results demonstrate important roles of these proteins in stress and 
inflammatory signals [8]. Studies have documented a key role for proinflammatory cytokine 
overproduction as a potential driving force for cartilage catabolism in OA [9]. One of the key signal 
transduction pathway involved in the production of proinflammatory cytokines is the p38 mitogen-
activated protein kinase (MAPK) pathway [10]. p38 MAPK has been reported as a primary signal 
transduction pathway activated by the degradative cytokines such as IL-1β and TNFα [2, 11]. This 
suggests that strategies to target signaling pathways that lead to cytokine overproduction should be 
explored in attempts to develop new OA therapeutics with the potential for disease modification. 
Given the dual anabolic and catabolic role of p38 pathway in cartilage, it remains unknown whether 
the inhibition of p38 pathway has some impact on cartilage from undergoing degeneration.  
SB203580, a pyridinyl imidazole that selectively inhibits p38 MAPK phosphorylation, has been widely 
used in vivo and in vitro studies to explore the function of p38 pathway. SB203580 has been 
demonstrated to attenuate the synthesis of inflammatory cytokines and MMPs in cartilage cells in 
several previous studies [12, 13]. One study has shown the decrease of chondrogenic phenotype in 
cartilage cells upon the addition of SB203580 [14]. Preclinical in vivo studies have shown that 
SB203580 inhibitors reduce inflammatory lung injury [15], rheumatoid arthritis [16] and cardiac 
dysfunction [17, 18]. Analysis of these data, collectively, suggests that the level of p38 
phosphorylation plays a direct role in cartilage homeostasis. Therefore, the aim of this study was to 
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investigate p38 pathway in OA tissue samples and assess the effects of SB203580 in normal rats and 
the rats challenged with OA. 
MATERIALS AND METHODS 
The study was conducted in compliance with the ethical principles derived from the Declaration of 
Helsinki and with the local institutional review board. All patients gave their informed consent to 
participate in this in vitro study (Ethics Number: 0700000157). Animal ethics approval for this project 
has been granted from the Queensland University of Technology and the Prince Charles Hospital 
Ethics Committees (Ethics number: 0900001134). Male Wistar Kyoto rats (11-12 weeks old) were 
purchased from Medical Engineering Research Facility (MERF) (Brisbane, Australia). Each animal 
weighing about 300-350 grams were used for this experiment. 
Isolation of cartilage cells: Normal articular cartilage chondrocytes (ACCs) were obtained from knee 
medial compartment tibial joint cartilage from tissue donors (n = 4) who were undergoing  above the 
knee amputations due to traumatic injury. Normal patients were healthy adults with no clinical signs 
or symptoms of joint, metabolic or hormonal diseases (osteoporosis). None of the patients were 
taking medications which might affect cartilage or bone metabolism. All patients selected for this 
study had ceased taking anti-inflammatory medication at least two weeks prior to surgery. Early 
stage OA patients were excluded if the samples showed any evidence of cartilage changes such as: 
softening of the hyaline articular cartilage; thinning and fibrous dislocation; ulcerations of the 
cartilage; and light sclerosis of the subchondral bone. OA ACCs (n=4) were sourced from the main 
defective area of medial compartment knee tibial joint cartilage from patients undergoing total knee 
replacement surgery. All radiographs were reviewed, and the patient samples were classified 
accordingly into three categories, on the basis of modified Mankin score [19, 20]. This score assesses 
structure (0-6 points), cellularity (0-3 points), matrix staining (0-4 points), and tidemark integrity (0-
1points), and has a maximum of 14 points. The final score for each cartilage was based on the most 
severe histologic changes observed in multiple sections from each specimen. The Mankin score was 
again divided into three stages depending on the score: grade 0-1 (normal cartilage), grade II (mild 
to moderate degenerative change, 2-9 points), and grade III (severe degenerative change, 10 or 
more points. In this study normal cartilage showed grade 0 and OA cartilage showed grade III 
cartilage. Chondrocytes were isolated from both normal and OA patients using enzymatic digestion 
as described previously [7, 21]. Passage 2-3 ACCs were used for the studies.  
Detection of MAPK-p38 activation in articular cartilage chondrocytes (ACC) pellet cultures:  2x105 
cells of normal ACCs and OA ACCs were resuspended in a serum free chondrogenic media (high 
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glucose DMEM supplemented with 10 ng/mL TGF-β3, 10nM dexamethasone, 50 mg/mL L-ascorbic 
acid, 10 mg/mL sodium pyruvate, 10 mg/mL proline, and ITS+ (final concentration: 6.25 mg/mL 
insulin, 6.25 mg/mL transferrin, 6.25 mg/mL selenious acid, 5.33 mg/mL linoleic acid, and 1.25 
mg/mL bovine serum albumin)) and centrifuged at 600 × g for 20 min to form a pellet. After two 
weeks of differentiation protein from pellets were isolated and western blot technique was applied 
to see the expression difference of P-p38 in normal and OA ACCs. 
In vitro inhibition of P-p38 pathway using SB203580 in normal ACC pellets:  P-p38 specific inhibitor, 
SB203580 was used to study the pathway mediated cellular phenotypic changes in the normal ACC 
pellets. Briefly, normal ACCs were incubated with or without the SB280580 after dissolving the 
concentrated stock solutions of each inhibitor in DMSO. The final concentration of DMSO never 
exceeded 0.1% (v/v) and the same amount of DMSO vehicle was added to the control medium. The 
medium was replenished every 3 days. Our previous experiments demonstrated an optimum 
concentration of 5uM of SB203580 for p38 inhibition in ACC pellets [7]. At these concentrations 
there was no observable change in the proliferation rates between control cells and inhibitor treated 
cells, nor was there any evidence of cytotoxicity, as assessed by LDH (lactose dehydrogenase) assays 
(data not shown). All experiments were performed in triplicate. After 2 weeks of differentiation in 
the presence or absence of inhibitor some pellets were stained with Alcian blue or immunostained 
with Type 10 Collagen (COL10) and Aggrecan (AGG) antibodies as described previously [7]. Some 
pellets were used to extract the total RNA to see the gene expression of hypertrophy and 
chondrogenic markers using protocols as described previously [7, 21].  
Rat OA models: Rats were anesthetized via intra-peritoneal injection with Zoletil (tiletamine 15 
mg/kg, zolazepam 15 mg/kg) and Xylazil (xylazine 10 mg/kg). OA was induced by transecting the 
medial collateral ligament just below its attachment to the meniscus, so that when the joint space 
opens, the meniscus is reflected toward the femur. The meniscus was then cut at its narrowest point 
without damaging the tibial surface, resulting complete medial meniscus transection. The surgical 
wound was then closed by suturing in two layers. A sham group on the left knee was subjected to 
the same surgical procedure, without the excision of the ligament or any meniscus manipulation. 
After the surgery, all rats received pain killer (Buprenorphine 0.05 mg/kg) and antibiotics 
(Cephalothin sodium 20 mg/kg, and Gentamicin 5 mg/kg).   
Study design and Drug administration: The rats were divided randomly into following four groups 
(n=12 (6 animals were used for histology + 6 animals for western blotting)). Group 1: Normal rats 
treated with DMSO + saline (vehicle alone), Group 2: normal rats treated with SB203580, Group 3: 
OA rats treated with DMSO + saline, and Group 4: OA rats treated with SB203580. Rats received 
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either intraperitoneal (i.p.) SB203580 (50 mg/kg in 0.25 mL) or diluents only (DMSO + saline). This 
concentration was chosen based on the published reports known to sufficiently raise plasma drug 
levels [22-24]. On the 30th day of the experimental period, the rats were euthanized with lethabarb 
(200 mg kg, i.p.); and the knee joints were collected for downstream observations. 
Morphological characterization: Whole knee joints were removed by dissection, fixed in 4% 
paraformaldehyde, and decalcified in 10% EDTA. After dehydration and paraffin embedding, serial 5 
µm sagittal sections from the lateral and medial compartment of the joint were cut. Two sections 
obtained at 100 µm intervals from the non weight bearing region and weight-bearing region of each 
knee joint were stained with safranin O–fast green. OA severity in the tibial plateau was evaluated 
according to modified Mankin histologic grading system (Mankin score: 0 to 14) [19, 20], and a 
cartilage destruction score was assigned for each knee sample by three independent assessors. For 
Safranin-O/Fast Green staining, 5μm paraffin-embedded sections of tibia from mice were counter-
stained with Haematoxylin before being stained with 0.02% aqueous Fast Green for 4 min (followed 
by 3 dips in 1% acetic acid) and then 0.1% Safranin-O for 6 min. The slides were then dehydrated and 
mounted with crystal mount medium.  
 
Cartilage thickness:  The depths of articular cartilage in medial compartment tibial knee was 
measured using semi automatic Image J software (NIH) using sections stained with saffranin-o which 
provided excellent color discrimination between bone and cartilage. The regions of interest on the 
femoral condyles were drawn using software and divided on the basis of the load bearing areas of 
the knee during locomotion. The total thickness of the cartilage was determined by measuring the 
distance from the medial compartment of superficial border of non calcified cartilage to boundary 
with the zone of calcified cartilage according to the length proportion. For each condylar section, the 
average of three measurements was used for statistical analysis.  
Western blotting : Total protein lysates were harvested by lysing the cartilage tissue samples with a 
lysis buffer containing 1 M Tris HCl (pH 8), 5 M NaCl, 20% Triton X140, 0.5 M EDTA and a protease 
inhibitor cocktail (Roche, Castle Hill, Australia). The cell lysate was clarified by centrifugation and the 
protein concentration determined by a bicinchoninic acid protein assay (Sigma, Castle Hill, Australia). 
5 microgram of protein was separated by electrophoresis on a 12 % sodium dodecyl sulfate-
polyacrylamide gel, transferred to a nitrocellulose membrane, and blocked with a Tris-Tween buffer 
containing 5% non-fat milk. The membranes were incubated with phosphorylated p38 or tubulin 
primary antibodies (1:000) overnight at 40C. After washing the membranes three times in TBS-Tween 
buffer they were incubated with anti-rabbit secondary antibody at 1:2000 dilutions for 1 hr. The 
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protein bands were visualized using the ECL Plus™ Western Blotting Detection Reagents (Amersham 
Biosciences, Castle Hill, Australia) and exposed on X-ray film (Fujifilm, Stafford, Australia).  
Immunohistochemistry: Immunohistochemistry was carried out using an indirect 
immunoperoxidase method. Tissue slices were dewaxed in xylene and dehydrated in ethanol. 
Endogenous peroxidases were blocked by incubation in 0.3% peroxide in methanol for 30 min 
following repeated washing in PBS. The sections were then incubated with proteinases K (DAKO 
Multilink, CA, USA) for 20 min for antigen retrieval. Next, all sections were treated with 0.1% bovine 
serum albumin (BSA) with 10% swine serum in PBS. Sections were then incubated with optimal 
dilution of primary antibody overnight at 4oC (P-p38 (Gene search PTY. Ltd, Queensland, 
Australia)=1:100, COL10 (Santa Cruz biotechnology, USA) =1:50, AGG (Millipore, New South Wales, 
Australia) =1:200, MMP-13 (Labvison, Fremont, CA)= 1:200). Optimum concentration of antibodies 
was determined by using a series of dilutions.  Next day, sections were incubated with a biotinylated 
swine-anti-mouse, rabbit, goat antibody (DAKO Multilink, CA, USA) for 15 min, and then incubated 
with horseradish perioxidase-conjugated avidin-biotin complex for 15 min. Antibody complexes 
were visualized by the addition of a buffered diaminobenzidine (DAB) substrate for 4 min and the 
reaction was stopped by immersion and rinsing of the sections in PBS. Sections were lightly 
counterstained with Mayer’s haematoxylin and Scott’s blue for 40 sec each, in between 3 min rinses 
with running tap water. Following this, they were dehydrated with ascending concentrations of 
ethanol solutions, cleared with xylene and mounted with a coverslip using DePeX mounting medium. 
Controls for the immunostaining procedures included conditions where the primary antibody or the 
secondary (anti-mouse IgG) antibodies were omitted. In addition, an irrelevant antibody (anti CD-
15), which was not present in the test sections, was used as a control. For semi-quantitative data, at 
400x magnifications, the positive cells were counted from each field of observation from medial 
compartment femur knee. At least three observation fields were selected from each section and 
three sections were selected from each sample. To eliminate the difference in total cell number in 
each observation field, the positive cell numbers were normalized to the cell number per 100 total 
cells in each specific group. 
TUNEL analysis: TUNEL is a specific immunohistochemical technique that enables sensitive and 
specific staining of the high concentrations of DNA 3-OH ends that are localized in apoptotic bodies.  
TUNEL analysis on tissue sections was performed by first permeabilizing the tissue with proteinase K 
solution for 30 min at 37⁰C. Following permeabilization, the slides were washed with PBS and the 
TUNEL reaction was performed using the fluorescein in situ cell death detection kit (Roche, Germany) 
following manufacturer’s protocol. As a positive control, sections were treated with DNase1 for 10 
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min at room temperature prior to labelling procedure to induce DNA strand breaks. The TUNEL 
reaction mixture / terminal transferace was omitted for the negative control. Slides were viewed and 
analysed using the microscope and % positive cells were calculated as described above.  
Behavioral studies: Behavior of the animals was monitored throughout the entire study period to 
assess any SB203580 side effects in drug treated vs. untreated animals. Some of the most common 
signs indicating the health status of a rat include observation of behavior (such as observation of 
unprovoked behaviour and responses to external stimuli), assessment of physical appearance 
(exophthalmia or enophthalmia (bulging or sunken eyes, respectively), nasal or ocular discharge, 
rough coat, and hunched back), and measurement of body weight. All these parameters were 
monitored and recorded carefully during the entire period of this study.   
Statistical analysis: Statistical analysis was performed by using the statistical Package from 
Graphpad prism (version 4.0).The unpaired student’s t-test was used for comparisons of P-p38 
expression in grade 0 and grade 4 cartilage, the differential expression of COL2, AGG, COL10, CBFA1, 
MMP-13 in the ACC culture, and the difference of positive cell numbers for AGG, COL10, MMP-13 in 
normal, sham and SB203580 application rats. The Mankin score and cartilage thickness in different 
treatment groups (normal+vehicle, normal+SB203580, OA+vehicle, and OA+SB203580) were 
subjected to one-way ANOVA and SNK tests. Data were expressed as the mean+/-SD. A p-value of 
less than 0.05 was considered to be statistically significant.  
RESULTS 
Patient Demographics: The mean age and body mass index (BMI) of OA study participants were 
63.7±2.8 years and 26.8±0.6 kg/m2 respectively. The mean age and BMI of normal study participants 
were 59.3±2.4 years and BMI 25.1±0.7 kg/m2 respectively. Both normal and OA cartilage samples 
were obtained from only males.  No significant statistical differences were observed with respect to 
all the above parameters when compared in between the groups. 
Increased p38 expression in cartilage tissue and ACCs collected from OA patients: Characterisation 
of normal and OA ACCs were performed to ensure the phenotypic stability by analysing the gene 
expression of COL2 and AGG. It was found that both normal and OA ACCs expressed significantly 
higher levels of COL2 and AGG. However, reduced levels of COL2 and AGG were observed in OA 
compared to normal ACCs (Fig 1A). Levels of phosphorylated p38 were determined in the protein 
lysate collected from normal articular cartilage chondrocytes (ACCs) and OA ACCs pellets after 
differentiating for two weeks under chondrogenic conditions. It was found that the levels of P-p38 
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were reduced significantly in OA ACCs compared to normal ACCs (Fig1B). Knee tibia joint sections 
from OA patients were collected and graded according to the disease severity based on Mankin 
scale. Immunohistochemistry further confirmed the in vitro findings showing the decrease of p38 
phosphorylated forms in OA cartilage tissue, suggesting that the p38 MAPK pathway may be more 
active in normal compared to OA cartilage (Fig 1C,D&E).  
In vitro inhibition of P-p38 pathway using SB203580 led to decrease of chondrogenic and increase 
of hypertrophic phenotype in normal ACCS: Normal ACC pellets were differentiated for two weeks 
in the presence or absence of SB203580. After two weeks, ACC pellets were stained with alcian blue 
to analyse the GAG deposition and chondrogenic phenotype. When normal ACC pellets were 
differentiated in the presence of SB203580, a decrease in the GAG deposition and AGG expression 
and the increase of hypertrophic marker, COL10, were found in ACC pellet cultures (Fig 2A). These 
observations were further confirmed by the gene expression showing the decrease in the expression 
of COL2 and AGG in the presence of SB203580 (Fig 2B). On the other hand, COL10, Runt-related 
transcription factor 2 (RUNX2) and MMP-13 were increased in the presence of SB203580, 
emphasizing the importance of this p38 signaling pathway in maintaining the cartilage function (Fig 
2C). 
Tissue p38 MAPK measures in rats: High basal activity of p38 was observed in the normal untreated 
animal groups compared to OA groups. Both normal and OA rats were treated with SB203580 (50 
mg/kg in 0.25 mL; i.p.) or diluents only (DMSO+saline). On the 30th day of experimental period, 
western blot with the cartilage homogenate was performed to verify whether that SB203580 inhibits 
activity of p38 MAPK in the in vivo cartilage. The results showed that the induction of p38 MAPK 
activity was suppressed significantly to a level far below baseline when animals were administered 
with SB203580 demonstrating the efficacy of the drug to block p38 activity (Fig 3A). Down-regulated 
P-p38 expression was associated with increased Mankin score (Fig 3B) and decrease in the cartilage 
thickness (Fig 3C). As expected, the Mankin score was 0 in untreated groups and of interest the 
degenerative changes were substantially increased in sham and OA animals upon administration of 
SB203580. 
Effect of SB203580 in the normal and OA induced rats:  After determining the efficacy of SB203580, 
both normal and an OA experimental animal model (induced by menisectomy) were used to 
evaluate the effects of SB203580 treatment on the development of the clinical and pathologic 
manifestations of the disease.  
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In the joints of normal (treated with vehicle alone) rats, no macroscopic changes were detected on 
the articular surfaces of femoral condyles and tibial plateau. Normal untreated animals showed the 
healthy-appearing cartilage with intact superficial, mild, and deep zones that stained deeply with 
safranin-O (red) for glycosaminoglycans. The chondrocytes were arranged in columns in untreated 
animals. However, when the animals were treated with SB203580, a significant loss of matrix 
staining was observed, which is consistent with decrease of P-p38 immunostaining in the cartilage 
(Fig 4A,B&C).  
When the effect of SB303580 was tested on the OA model, it was found that the menisectomy 
induced OA knees revealed an extensive degeneration of cartilage, surface roughness, fibrillation, 
small osteophytes or areas of peripheral fibrous tissue proliferation, both in tibia and femur where 
the meniscus was removed; however the damage appears much higher when OA models were 
treated with the SB203580 (Fig 4A,B&C). These results collectively indicate the inhibition of p38 
pathway led to more severe damage to the structure of cartilage.  
Expression of cartilage markers and hypertrophy markers in the SB203580 treated animals: 
We found a strong presence of AGG (78% of total cartilage area) protein expression in articular 
cartilage of normal rats (treated with vehicle alone), whereas cartilage of the normal knee cartilage 
treated with SB203580 showed minimal, AGG (40% of total cartilage area) staining (Fig 5 A,B&C). 
These data indicated to us that the deprived expression of p38 expression led to phenotypic changes 
of cartilage even in the normal animals. In contrast to the above findings we found that the 
expression of COL10 (Fig 5 D,E&F) and MMP-13 (Fig 5 G,H&I) were significantly upregulated in 
normal animals treated with SB203580 compared with corresponding controls, which indicated a 
transition to hypertrophy phenotype in the absence of P-p38 pathway.  
Enhanced expression of TUNEL positive chondocytes in the SB203580 treated animals: Cartilage 
degradation of the joint is characteristically accompanied by apoptosis related cascades. To test this 
hypothesis, normal rats that were treated with SB203580 were examined for apoptosis using the 
TUNEL assay. Very few apoptotic (TUNEL-positive green fluorescent) cells were observed in cartilage 
from untreated rats. Treatment with SB203580 caused a modest increase in number of apoptotic 
cells in the cartilage (Fig 6 A,B&C). These results clearly demonstrate that decrease in the p38 
phosphorylation is capable of inducing apoptosis of cartilage cells even in the normal rats.  
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Animal behavioural studies: No significant differences were found with respect to behavior, 
assessment of physical appearance, and measurement of body weight in SB203580 treated vs. 
untreated animals (data not shown). 
DISCUSSION 
Growing evidence shows that the reversal of structural remodelling represents a key therapeutic 
target in OA management and treatment. Given the central role of p38 kinase in the regulation of 
cellular stress response mechanisms, modulation of p38 kinase activity represents an attractive 
therapeutic approach in the treatment of several diseases. Indeed, small molecule p38 inhibitors 
have been suggested to have potentially beneficial effects in pulmonary disease [25], septic shock 
[24], and rheumatoid arthritis disease [26]. The concept of manipulation of the phosphorylation 
level of p38 as a potential treatment for OA disease is based on the assumption that p38 kinase is 
activated in these diseases. However, it is surprising to note that the detailed change in p38 kinase 
activity during OA cartilage has not been previously reported.  
Here, we found that phosphorylated p38 is highly expressed in normal human cartilage, which 
suggests that cartilage must generate significant levels of P-p38 for tissue maintenance and 
homoeostasis. However, P-p38 is significantly reduced in diseased OA cartilage, confirming and 
expanding on our previous data for P-p38 levels at cellular level of normal and OA chondrocytes. In 
line with this evidence, P-p38 expression is significantly down regulated in OA animal model in vivo, 
raising the possibility that those alterations in P-p38 expression is associated with the earliest stages 
of OA pathogenesis.  
To understand the precise role of p38 pathway, normal chondrocytes pellets were incubated with 
SB203580 to inhibit the phosphorylation of p38 pathway. We found that the lack of p38 expression 
led to decrease in chondrogenic phenotype and increase in the hypertrophic phenotype. Consistent 
with our results, Li et al showed regulation of chondrogenesis by p38 pathway with a delicate 
balance, interacting with the TGF-beta1/Smads signalling pathway [27]. Similarly, Zhang et al, by 
using the genetic inhibition studies they showed role of p38 in chondrocytes differentiation and 
suggests that Sox9 is a downstream target of the p38 MAPK pathway [28]. Furthermore, it has been 
shown previously that complete disruption of p38 is lethal, suggesting that maintenance of normal 
levels of p38 activity is necessary for the normal embryonic development [29]. The data obtained in 
this study show that apoptosis in normal rat cartilage (TUNEL-positive chondrocytes) was 
significantly increased when treated with p38 inhibitor. These observations suggest that a significant 
proportion of chondrocytes die by apoptosis in the absence of basal p-38 phosphorylation levels. 
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Under normal conditions mature articular chondrocytes are kept in a state of maturational arrest. In 
contrast to this phenotype, it has been shown that OA chondrocytes express hypertrophic 
differentiated markers such as COL10, ALP and RUNX2 [30]. It has been reported that hypertrophy of 
chondrocytes can lead to the degenerative changes in the cartilage by upregulating the expression of 
MMP’s [31]. These results together indicate that loss of P-p38 activity can lead to phenotypic 
changes of articular chondrocytes to a hypertrophic phenotype which could be pathological to the 
adult mature cartilage structure. In line with our findings, Stanton et al showed elevated RUNX2, 
Osterix and Osteocalcin transcript levels in chondrocyte cultures upon inhibition of p38 activity with 
the pharmacological inhibitor, suggesting loss of p38 signalling leads to chondrocytes hypertrophy 
during skeletal maturity [4]. 
At in vivo level, we demonstrated for the first time, an inhibitor for p38 pathway (SB203580) 
worsened the cartilage degeneration both in normal and OA animal models, evidenced by increase 
in Mankin score and decrease in the cartilage thickness. The decrease of P-p38 levels was associated 
with decrease in chondrogenic and increase in hypertrophy phenotype. Consistent with our findings 
it has been recently demonstrated that the genetic reduction of p38 MAPK activity in cartilage leads 
to phenotypic changes in bone and/or cartilage in adult mice [32]. 
Although this study suggests a protective role for p38 kinase both in vitro and in vivo, a number of 
studies showed the destructive role of p38 when it is upregulated. It has been reported that 
upregulated p38 phosphorylation levels can lead to increased cytokine production by several 
mechanisms such as direct phosphorylation of transcription factors [33]. One study has also found 
that the attenuation of cartilage degeneration and OA pain in animal models due to upregulated p38 
levels and suggests that p38 inhibitors may be a useful approach for the treatment of OA [34].   
These results indicate the phosphorylation levels of p38 need to be well-balanced in a physiological 
level in order to maintain cartilage health and both inhibition and upregulation of the p38 signaling 
are detrimental to cartilage. Several studies do support a considerable cross-talk between the 
different MAPKs subtypes, including interactions between inflammatory/stress-activated signal 
pathways and hormone/growth factor-activated signal pathways [35].  In our previous study we 
demonstrated the cross-talk between ERK and p38 pathways and showed an upregulation of ERK 
phosphorylation levels can lead to decrease of P-p38 levels and vice versa, which in turn can lead to 
cartilage hypertrophy and degradation, indicating the dynamic and balanced interactions of MAPK 
pathways are required for cartilage homeostasis [7].   
Key messages:  
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1. The present study revealed reduced p38 kinase activity as a causative factor in OA  
2. Normalization of p38 kinase activity may represent a new preventive approach against 
progression of OA.  
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 FIGURE LEGENDS 
Figure 1: Down-regulation of phosphorylated p38 activity in cartilage collected from OA patients. 
(A) Characterisation of normal and OA ACCs were performed by analysing the gene expression of 
COL2 and AGG at day 14 chondrocyte pellets. A representative gel image was shown.  (B) Western 
blot analysis of chondrocytes showed the decrease of p38 phosphorylated forms in OA patients 
compared to normal patients. Band density quantification was performed using Image J software for 
phospho-p38. Each value represents protein bands from three separate experiments. The mean ± SD 
is shown. * Represents a significant difference (p<0.05). (C, D&E) Articular cartilage collected from 
lateral compartment with mild OA cartilage (D) contained more P-p38 positive cells compared with 
medial compartment severe OA cartilage. Arrows point to some of the positive cells (E). No staining 
was observed in the negative control sections (C). Scale bar: 100µm. 
Figure 2: Effects of p38 inhibitor SB203580 on normal ACCs matrix deposition and gene expression 
(A) Alcian blue staining showed significant decrease in the GAG deposition in ACC pellets treated 
with SB203580. Similarly, immunostaining for AGG showed a decreased staining pattern in ACCs 
cultured in the presence of SB203580. On the other hand, the expression of hypertrophic marker 
COL10 was increased when pellets were cultured in the presence of SB203580. Arrows point to 
some of the positive cells. Scale bar=100µm. (B-C) qPCR showed that chondrogenic markers such as 
COL2 and AGG were downregulated and hypertrophic markers such as COL10, RUNX2, and MMP-13 
were significantly upregulated in ACCs pellets cultured with SB203580. mRNA levels were 
normalized against GAPDH and 18s and the relative gene expression is presented. Results are shown 
as mean ± SD (n=4). * Represents a significant difference (p≤0.05). 
Figure 3: Inactivation of p38 kinase after treating animals with SB203580 and this lead to increased 
cartilage Mankin score and decreased cartilage thickness. (A) P-p38 activity levels were reduced to 
a level far below baseline when normal animals were administered with SB203580 demonstrating 
the efficacy of the drug to block p38 activity. A representative bands obtained from six different 
animals with similar results were shown. (B&C) Graphs showing the increased Mankin score and 
decreased cartilage thickness both in normal and OA rats that were treated with SB203580, 
indicating that the lack of P-p38 activity is pathological for the articular cartilage. Results are shown 
as mean ± SD (n=6). * Represents a significant difference (p≤0.05). 
Figure 4: Histological findings demonstrating the detrimental effects on the cartilage of rats 
treated with SB203580. (A) Gross morphological cartilage changes in the normal and menisectomy 
(MNX) induced OA rats that were treated with or without SB203580.  L: Lateral compartment; M: 
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medial compartment). Arrows point to damaged surface area.  (B) Saffranin-O staining 
demonstrated higher rate of proteoglycan depletion both in normal and OA animal models when 
treated with SB203580 compared to their respective controls. Scale bars: 100µM.  (C) 
Immunostaining showing that p38 phosphorylation was significantly decreased in the animal models 
treated with SB203580. Scale bar: 50µm.  
Figure 5: Reduced chondrogenic phenotype and increased hypertrophic expression in rats treated 
with SB203580 compared to vehicle alone treated controls. Articular cartilage from SB203580 
treated rats (B) contained less AGG compared to untreated animals (A).  The percentage of AGG 
positive cells also showed the same trend (C). In contrast, the expression of COL10 in normal rat (D) 
was lower than SB203580 treated rat (E). The percentage of COL10 positive cells were also increased 
in normal rats treated with SB203580 (F). Similarly, MMP-13 in normal rat (G) was lower than 
SB203580 treated rat (H). The percentage of MMP-13 positive cells showed similar pattern (I). 
P≤0.05 was considered significant (n=6). Scale bar=200µm.  
Figure 6: Enhanced apoptosis in SB203580 treated normal rat. (A&B) TUNEL assay reveals an 
enhanced number of apoptotic chondrocytes in SB203580 treated normal rats, whereas only few 
apoptotic chondrocytes are seen in the untreated animals. An overlapped image shows that TUNEL 
positive cells (green) with nucleus (DAPI, Blue). Arrows point to some of the positive cells. Scale bar= 
75 µm (B) Percentages of total cell counts that are TUNEL positive. * P<0.05, n=6 per group. 
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